The team behind
BioPhenyx (and roles) are:
Morten Frödin (COO)
Morten is Co-inventor of the CRISPR-Select technology, from a basis of expert knowledge of general gene-editing technologies and generation of cell and mouse models of human genetic disease. He is Associate Professor at BRIC and has been affiliated with BRIC since 2004, Frödin Group – University of Copenhagen (ku.dk). His research and research group are at the forefront in genome editing technologies, having spent a decade developing precision CRISPR-based approaches.
Claus Storgaard Sørensen (CSO)
Claus is Co-inventor of the CRISPR-Select technology, from a basis of expert knowledge of disease mechanisms within cancer diseases, such as breast and ovarian cancers. He is Associate Professor at BRIC and has been affiliated with BRIC since 2004, Sørensen Group – University of Copenhagen (ku.dk). His research and research group are at the forefront in functional genetic screening and DNA damage/genome instability research, with a multitude of international collaborations with academia and industry.
Ole Bitsch-Jensen (CEO)
Ole has worked within life science for 3 decades; in big pharma (Roche – Doing now what patients need next), in startup biotech (Nordic Bioscience), and as investor with Seed Capital (Seed Capital – The strongest local partner). He has been founding investor of some 15 life science companies e.g., MinervaX (MinervaX) and 2cureX (The power of precision. For every oncologist. Today. | 2cureX). In parallel to his engagement in BioPhenyx, he is Senior Partnership Manger with Coloplast (Coloplast – Corporate) the largest medical device company in Denmark.